secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001104659-25-092957
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering signs $25M Sanofi placement contingent on public offering; Phase 2a pancreatic data shows 86% OS
--------------------------------------------------------------------------------

- Sanofi subsidiary Aventis agrees to purchase $25M in stock at public offering price; closing contingent on $75M+ public offering by Sept 26, 2025.
- Updated Phase 2a atebimetinib + mGnP data in 1L pancreatic cancer (N=34): 86% OS at 9 mos (vs ~47% SOC), median PFS 9.6 mos, median OS not reached.
- Safety profile: Grade ≥3 TEAEs in ≥10% were anemia (24%) and neutropenia (18%); no Grade 5 events.
- Near-term milestones: regulatory feedback on Phase 3 plans in Q4 2025; potential Phase 3 start by end 2025 and first patient by mid-2026.
- Leerink Partners and Oppenheimer & Co. act as joint bookrunners for the public offering and placement agents for private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/0001104659-25-092957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000110465925092957/tm2526843d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-092957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer